Subscribe
Strategy
3 min read

An ER chain just put an AI scribe in 70% of its hospitals. That's the enterprise tipping point for vet AI.

VEG ER for Pets has deployed VetRec's AI documentation across more than 70% of its hospitals after a six-month pilot. The enterprise buy-in, not the technology, is the signal: AI scribes have crossed into multi-site standardization.

Written by
The Underbite
Published on
June 12, 2026
An ER chain just put an AI scribe in 70% of its hospitals. That's the enterprise tipping point for vet AI.

Most veterinary AI scribe stories are single-clinic pilots. This one isn't. A national emergency-only chain has taken VetRec's documentation tool live across more than 70% of its hospitals after a six-month pilot, with a full rollout underway. The detail that matters: enterprise vet groups are now standardizing on AI documentation, and they're doing it in the hardest setting to make it work.

VEG takes VetRec live across 70% of its ER network

VEG ER for Pets ran a six-month pilot with VetRec, an enterprise-grade veterinary AI assistant, before committing to a company-wide deployment. Across the initial pilot sites, VEG clinicians logged more than 100,000 visits on the tool.

The product writes clinical documentation from the visit so scribes and clinicians spend less time typing and more time on cases. VEG and VetRec say the two companies worked across leadership, operations, and clinical teams to adapt the tool to emergency workflows, which move faster and carry higher acuity than general practice.

Emergency is a deliberate proving ground. If AI documentation holds up in a 2 a.m. critical case, the general-practice version is the easy version. The rollout reaching 70% of hospitals signals the pilot cleared whatever internal bar VEG set for accuracy and clinician adoption.

Why enterprise scribe adoption changes the labor math

The interesting part isn't the technology. AI scribes have been demoed across the industry since 2023. It's the buyer. A multi-site veterinary group standardizing on one documentation vendor is the kind of enterprise reference account that pulls the rest of the category forward, the way a marquee hospital system does in human health IT.

Documentation time is a direct throughput and burnout lever, and both are acute in emergency medicine. Every minute a clinician spends writing records is a minute not spent on the next patient or the next client conversation. In a setting where staffing is the binding constraint, time returned to the floor is effectively added capacity without added headcount.

That lands squarely on the structural problem the rest of the category is staring at. With clinical visit volume forecast to stay flat-to-down through 2030 on demographic grounds, growth has to come from value and throughput per visit, not more visits. AI documentation is the clearest current expression of clinics pulling that lever. Seen that way, VEG's rollout isn't a tech-adoption story. It's a margin-defense story dressed as one.

For vet software vendors, the competitive read is sharper. The scribe market is shifting from "does it work" to "who wins the multi-site contracts." VetRec landing VEG follows its tie-ups with other group buyers, and the pattern suggests the category is consolidating around a few enterprise-grade players rather than a long tail of clinic-by-clinic tools. The reference logos will increasingly decide the winners.

For independent clinics outside the enterprise tier, the takeaway is a benchmark. A national chain just validated AI documentation at scale in the toughest environment. The question for a standalone practice is no longer whether the tooling is ready. It's what the labor-cost gap looks like against groups that have already deployed it.

What the company-wide rollout signals for vet AI vendors

The next marker is whether VEG completes the rollout to 100% and publishes hard numbers, documentation time saved, cases per shift, retention. Pilot-stage adoption metrics like 100,000 logged visits show uptake. Throughput and retention data would show return, and that's what turns a reference account into a category-defining case study.

The vendor shakeout: Watch which scribe vendors announce the next multi-site enterprise deals. The buyers signing now are setting the defaults that smaller clinics inherit later, and each enterprise win raises the bar for everyone else competing for the same logos.

The integration question: The durable moat won't be transcription quality, which converges fast. It'll be how deeply the tool wires into practice management, billing, and compliance. That's the layer to watch as these deals mature.

For an industry being told volume growth is gone for a decade, tools that lift the value of each visit stop being a nice-to-have. VEG just put a number on how fast a serious buyer will move.

Source: VEG ER for Pets via PR Newswire

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Funding & M&A
4 min read

Vetspire Splits From Thrive, Lands a Battery Ventures Backing

Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.

Read article
Read article
PetMeds Revenue Falls 20% as Takeover Fight Drags On
Earnings
6 min read

PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.

Read article
Read article
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
Regulatory
4 min read

FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North

The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.

Read article
View all articles